Biotechnology company Ridgeback Biotherapeutics LP reported on Thursday the receipt of the US Food and Drug Administration's (FDA) orphan drug designation for the experimental mAb114 treatment for Ebola.
According to the company, mAb114 is a monoclonal antibody, a protein that binds to a single target on a pathogen and isolated from a human survivor of the 1995 Ebola outbreak in Kikwit, a city in the DRC. The survivor reportedly retained antibodies against Ebola 11 years after infection.
The drug has completed a Phase 1 safety study and is currently being used to treat Ebola patients in Congo under two separate protocols.
Under the first protocol, the company will launch a randomised controlled trial to evaluate mAb114 for efficacy and safety in the treatment of Ebola patients in partnership with the World Health Organisation and led and sponsored by the DRC's National Institute for Biomedical Research (INRB) , the DRC Ministry of Health, the US National Institute for Allergy and Infectious Diseases (NIAID), the Alliance for International Medical Action (ALIMA) and other organisations.
As part of the second protocol, the company will begin an expanded access programme of mAb114 in line with the WHO ethical framework known as Monitored Emergency Use of Unregistered Interventions (MEURI), which allows for access to investigational therapeutics outside of clinical trials.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary